Skip to main content

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

*February 2020*

Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and other oncogenic drivers has helped further lung cancer research and patient care. In the interview, Dr. Salgia discusses current and future directions in the treatment of patients with lung cancer with MET alterations. Read more.